SUMMARY
We present a systems strategy that facilitated the development of a molecular signature for glioblastoma (GBM), composed of 33 cell-surface transmembrane proteins. This molecular signature, GBMSig was developed through the integration of cell-surface proteomics and transcriptomics from patient tumors in the REMBRANDT (n=228) and TCGA datasets (n=547) and can separate GBM patients from controls with an MCC value of 0.87 in a lock-down-test. Functionally, 17/33 GBMSig proteins are associated with TGFβ signaling pathways, including: CD47, SLC16A1, HMOX1 and MRC2. Knockdown of these genes impaired GBM invasion, reflecting their role in disease-perturbed changes in GBM. ELISA assays for a subset of GBMSig (CD44, VCAM1, HMOX1, and BIGH3) on 84 plasma specimens from multiple clinical sites revealed a high degree of separation of GBM patients from healthy controls (AUC 0.98 in ROC). Additionally, a classifier based on these four proteins differentiated the blood of pre- and post-tumor resections, demonstrating potential clinical value as biomarkers.